Seroatlas · Human Serome Atlas

LYG1

Lysozyme g-like protein 1

Also known as: LYG1_HUMAN, LYGA1, SALW1939

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8N1E2
Gene: LYG1
Ensembl: ENSG00000144214
Chromosome: 2
Canonical length: 194 aa
Protein class: Predicted secreted proteins
Secretome location: Secreted in other tissues

OverviewNCBI Gene

Predicted to enable lysozyme activity. Predicted to be involved in defense response to Gram-positive bacterium. Predicted to be active in extracellular region. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

194 residues, UniProt reviewed canonical sequence.

>Q8N1E2|LYG1
     1  MSALWLLLGL LALMDLSESS NWGCYGNIQS LDTPGASCGI GRRHGLNYCG VRASERLAEI
    61  DMPYLLKYQP MMQTIGQKYC MDPAVIAGVL SRKSPGDKIL VNMGDRTSMV QDPGSQAPTS
   121  WISESQVSQT TEVLTTRIKE IQRRFPTWTP DQYLRGGLCA YSGGAGYVRS SQDLSCDFCN
   181  DVLARAKYLK RHGF

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LYG1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.31
Highest tissue expression: 23 nTPM

Expression across tissuesHPA

Tissue

kidney: 23 nTPM
liver: 5.6 nTPM
testis: 5.3 nTPM
spleen: 4.5 nTPM
cerebellum: 3.9 nTPM
cervix: 3.3 nTPM

Single-cell type

cardiomyocytes: 27 nCPM
myonuclei: 21 nCPM
thymic myoid cells: 19 nCPM
retinal horizontal cells: 16 nCPM
epicardial cells: 16 nCPM
retinal ganglion cells: 16 nCPM

Immune cell

T-reg: 0.5 nTPM
eosinophil: 0.2 nTPM
gdT-cell: 0.2 nTPM
MAIT T-cell: 0.2 nTPM
naive CD4 T-cell: 0.2 nTPM
classical monocyte: 0.1 nTPM

Brain region

cerebellum: 11 nTPM
white matter: 7.1 nTPM
cerebral cortex: 6.3 nTPM
pons: 5.7 nTPM
basal ganglia: 5.6 nTPM
thalamus: 5.6 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.37
gnomAD pLI: 0
gnomAD missense Z: 0.58
DepMap mean gene effect: 0.09
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

lysozyme activity

Cellular components

extracellular region

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LYG1 as an antibody target. Whether an autoantibody or antibody against LYG1 could matter depends on whether native LYG1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LYG1 is annotated as secreted, so native LYG1 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label LYG1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...